ArticleScientific reports2023
A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Eco-friendly spectrophotometric approach for the determination of anti-diabetic drugs in fixed-dose formulation together with metformin's toxic impurity: comprehensive method assessment.Scientific reports · 2026Article
- The first validated HPLC method with UV detection for concurrent assay of lidocaine and fluorescein in their co-formulated ophthalmic solution.BMC chemistry · 2026Article
- A sensitive, aqueous-based spectrofluorimetric approach for the determination of favipiravir in presence of its acid-induced degradation product.BMC chemistry · 2026Article
- Sustainable dual-drug analysis: a synchronous spectrofluorimetric approach with integrated greenness and whiteness metrics for favipiravir and levofloxacin.Scientific reports · 2026Article
- Article
- A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities.BMC chemistry · 2025Article
- Eco-friendly spectrofluorimetric determination of remdesivir in the presence of its metabolite in human plasma for therapeutic monitoring in COVID-19 patients.Scientific reports · 2025Article
- Article
- Advancing Green Chemistry in Antiviral Therapeutics: A Comprehensive Review.Current drug research reviews · 2025Review
- Article
- Article
- Advanced chemometric methods for simultaneous quantitation of caffeine, codeine, paracetamol, and p-aminophenol in their quaternary mixture.Scientific reports · 2024Article
- Establishment of an HPLC Fingerprint and Cluster Analysis for Miao Ethnic MedicineIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During COVID-19 pandemic, Favipiravir (FPV) showed a great efficacy against COVID-19 virus, it produced noticeable improvements in recovery of the patients. The aim of this study was to develop a new, green and simple method for the simultaneous determination of FPV and its acid-induced degradation product (ADP) in its pure and pharmaceutical dosage forms. This method will be key for the inevitable development of FPV solution and inhaler formulations. A green micellar RP-HPLC method was developed using an RP-VDSPHERE PUR 100 column (5 µm, 250 × 4.6 mm) and an isocratic mixed micellar mobile phase composed of 0.02 M Brij-35, 0.1 M SDS and 0.01 M potassium dihydrogen orthophosphate anhydrous and adjusted to pH 3.0 with 1.0 mL min
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.